Log in or Sign up
to access My Account functionalities
DHPC for Remicade: Use of live vaccines in infants exposed in utero or during breastfeeding
This letter contains notification of a revised 12-month waiting period (currently 6 months) for administration of live vaccines to infants exposed to infliximab during the latter parts of pregnancy and the new recommendation not to administer live vaccines to an infant being breastfed by a mother who is treated with infliximab.